þ T cells from a stem cell transplant (SCT) can reduce the incidence of graft-versus-host disease (GVHD) while preserving antimicrobial and perhaps antileukemia activity. However, the most effective methods for allodepleting T cells prior to transplant have not been determined. In this study, we have compared three agents that deplete CD25 þ activated, alloreactive T cells. These included Ontak (Denileukin Diftitox), an IL-2 fusion toxin, anti-CD25 microbeads (MACS), an anti-CD25 immunotoxin (IT) and a combination of the IT and MACS. Peripheral blood mononuclear cells (PBMCs) activated in a primary mixed lymphocyte reaction (MLR) were allodepleted using optimal amounts of each agent, and the cells were then analyzed by flow cytometry. The treated cells were examined both for remaining alloreactivity and for the preservation of third party reactivity by testing them in a secondary MLR. Our data demonstrate that both the anti-CD25 IT and the anti-CD25 MACS were equally effective in depleting CD4
Introduction
Hematopoietic stem cell transplantation (HSCT) is often the only available curative management for many hematological malignancies and for inherited immune disorders. However, this procedure is associated with a high incidence of severe graft-versus-host disease (GVHD), its major cause of morbidity and mortality. 1, 2 Forty to fifty nine percent of recipients with HLA-matched HSCT and up to 80% of patients receiving transplants with two to three mismatched HLA antigens, suffer from acute GVHD even with immunosuppressive prophylaxis. 3 During GVHD, donor T cells are activated by alloantigens on cells from the recipient, and these cells attack tissues such as skin, liver and the gastrointestinal tract. 4 Both helper CD4 þ and cytotoxic CD8
þ T cells are involved in initiating GVHD. Complete depletion of donor T cells from the graft is effective in preventing GVHD, but it is also associated with delayed recovery of T cell function often leading to fatal infections and a decreased graft-versus-leukemia (GVL) effect. 5, 6 Therefore, depletion of only the alloreactive lymphocytes would be more desirable.
Among the different methods used to selectively deplete alloreactive lymphocytes are the CD25-reactive IT, RFT5-deglycosylated ricin A chain (dgA); Ontak, fusion protein containing fragments of diphteria toxin and human interleukin-2 (IL-2); and anti-CD25 microbeads. Previous studies have suggested that ex vivo selective depletion (SD) of CD25 þ alloreactive cells with this IT reduces alloreactivity, but does not impair immune function. 7, 8 Several studies have been carried out using this particular IT to deplete alloreactive cells prior to transplantation and results have been encouraging. [8] [9] [10] [11] [12] Ontak has been used for the treatment of patients with relapsed or refractory cutaneous T cell lymphoma (CTCL), 13 but its effectiveness in allodepleting T cells has not been investigated. The use of MACS to deplete CD4 þ or CD8 þ T cells from transplants has shown promise in several clinical trials in highrisk patients 14, 15 and anti-CD25 MACS have effectively depleted alloreactive cells in vitro. 16, 17 For methods that have a common goal (in this case allodepletion), it is important to compare them under optimal conditions in the same experimental system. Unfortunately, this is not often done. Because our IT appears to be so promising in patients, we felt it important to compare it to both Ontak and anti-CD25 MACS. This comparison was also of practical importance, since both Ontak and MACS are commercially available, while our IT is not. In addition, we combined the best two agents and compared them to each alone. Depletion was determined by both flow cytometry and by remaining alloreactivity against the same or third party cells. Our results suggest that the IT, MACS or the combination of the two were equally effective in depleting alloreactive CD4 þ CD25 þ cells, but that the IT more effectively depletes alloreactive CD8 þ CD25 þ cells. The allodepleted cells retained third party reactivity. In contrast, Ontak depleted alloreactive cells very poorly.
Methods

Preparation of cells
Informed consent was obtained from each healthy subject and up to 150 ml of peripheral blood was collected into multiple 8.5 ml Vacutainer tubes (VWR Scientific Products, West Chester, PA, USA) containing the anticoagulant Adenine Citrate Dextrose (ACD). Twenty milliliter of whole blood was diluted 1:1 with sterile phosphate-buffered saline (PBS, Invitrogen, Carlsbad, CA, USA) and centrifuged in 50 ml conical tubes (Becton Dickinson, Franklin Lakes, NJ, USA) over 12 ml Histopaque-1077 (SigmaAldrich, St Louis, MO, USA). Peripheral blood mononuclear cells (PBMCs) forming a layer at the plasma/ Histopaque interface were harvested and then washed three times with 50 ml PBS. Viable cells were counted on a hemocytometer following Trypan blue (Invitrogen, Carlsbad, CA, USA) staining and were then resuspended in complete cell culture medium. Medium was prepared by filtration through a 0.22 mm vacuum driven filtration system (Millipore, Bedford, MA, USA) and consisted of cell culture medium X-VIVO 15 (BioWhittaker, Walkersville, MD, USA) supplemented with 10% heat-inactivated, human AB serum (Valley Biomedical, Winchester, VA, USA), 1% Heparin (Baxter, Deerfield, IL, USA) and 1% mixture of Penicillin, Streptomycin and Amphotericin B (Invitrogen, Carsbad, CA, USA). All procedures were performed under sterile conditions inside a biological safety cabinet. Isolated cells were incubated at 371C in an atmosphere of 5% CO 2 .
Allodepletion
Ontak. Ontak (DAB 389 IL-2, Denileukin Diftitox) is a recombinant DNA-derived fusion protein containing the catalytic and membrane translocation domains of diphtheria toxin (fragments A and B) and the complete amino-acid sequences of IL-2. 18 Ontak selectively targets the highaffinity IL-2 receptor expressed on malignant and activated cells. 19 The drug is marketed by Ligand Pharmaceuticals, San Diego, CA, USA and was approved in 1999 by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory CTCL. 13 Ontak is distributed in vials at a concentration of 300 mg/2 ml in a solution of citric acid (20 mM), polysorbate 20(o1.0%) and EDTA (0.05 mM).
Anti-CD25-IT (Anti-CD25-deglycosylated ricin toxin A chain (dgA) orRFT5-dgA). The anti-CD25 immunotoxin was prepared by chemically coupling dgA to the anti-CD25 murine IgG1 MAb, RFT5, using the heterobifunctional crosslinker succinimidyloxycarbonyl-{alpha}-methyl-{alpha}-(2 pyridyldithio) toluene (SMPT) (Pierce, Rockford, IL, USA), as previously described. 20 Aliquots of the anti-CD25 IT were stored at À701C at the concentration of 5 mg/ml in sterile 0.85% NaCl containing 5 mM lysine.
MACS. Anti-CD25 microbeads (Miltenyi, Auburn, CA, USA) can be used for depletion or positive selection of CD25 þ cells from PBMCs activated by antigens, mitogens, or allogens. 21 Colloidal super-paramagnetic microbeads are conjugated to an IgG1 anti-human CD25 Mab recognizing epitope A on the CD25 molecule. In this study, we used anti-CD25 microbeads to deplete activated CD25 þ T cells.
Depletion of PHA-activated CD4 þ CD25 þ lymphocytes by the IT, Ontak or MACS PBMCs were cultured for 4 h with 5 mg/ml of phytohemagglutinin (PHA) (Sigma, St Louis, MO, USA) followed by the addition of 0.01 mg/ml sterile IL-2 (Roche, Indianapolis, IN, USA, 10 000 U) for another 48 h to support the growth of the activated T cells. 22 The cells were incubated in 75 cm 2 flasks (Corning, NY, USA) at a concentration of 5 Â 10 6 cells per ml of complete medium. After 2 days, the cells were washed three times with sterile PBS to remove IL-2 and the percentage of CD25 þ cells was determined by flow cytometry. The activated cells were divided into three aliquots and depleted by MACS, Ontak or the IT.
MACS. PHA-activated lymphocytes were washed twice by centrifugation in 20 ml cold buffer containing sterile PBS supplemented with 0.5% bovine serum albumin (Sigma, St Louis, MO, USA) and 2 mM EDTA (Sigma, St Louis, MO, USA). The cell pellet was resuspended in 80 ml buffer per 1 Â 10 7 cells and the cells were magnetically labeled by adding 20 ml of anti-CD25 microbeads per 10 IT or Ontak. PHA-activated cells were mixed with either the IT or Ontak at a dose 10 À8 M 23 and cultured for 24-72 h. The IT was added along with 6 mM NH 4 Cl (Abbott Laboratories, North Chicago, IL, USA), which is an IT enhancer. 7 The cells were incubated in 24-well cell culture flat bottom cluster plates (Corning, NY, USA) at a concentration of 10 6 cells/ml. The treated cells were analyzed for expression of CD25 by flow cytometry at 24-h intervals over the next 3 days. Untreated activated cells were also cultured and used as a control. After treatment with 10 À7 M Ontak, the cell viability decreased.
Concentrations of 10
À8
-10 À10 M were therefore used in subsequent experiments.
Selective depletion of CD4
þ CD25 þ cells activated in a primary mixed lymphocyte reaction using the IT, Ontak, or MACS PBMCs isolated from the blood of a healthy donor were activated in a one-way mixed lymphocyte reaction (MLR) by co-culturing the cells with irradiated (25 Gy) stimulator PBMCs from an unrelated individual. The cells were incubated in 75 cm 2 flasks (Corning, NY, USA) in complete medium at ratio of 5:1 responder to stimulator cells, so that the final concentrations of responder and stimulator cells were 5 Â 10 6 and 1 Â 10 6 /ml, respectively. The cells were incubated at 371C in 5% CO 2 on a rocking platform for 72 h.
The activated cells were divided into aliquots and allodepleted by MACS, or cultured with Ontak or the IT þ 6 mM NH 4 Cl at doses ranging from 10 À8 to 10 À10 M for 24, 48 and 72 h. Control cells were treated with 10 À8 M anti-CD22 IT þ 6 mM NH 4 Cl. Cells treated with the IT, anti-CD22 IT or Ontak were cultured in 24-well flat bottom plates at a concentration of 1 Â 10 6 donor cells per ml. The expression of CD25 on the activated and allodepleted cells was determined by flow cytometry.
Reactivation of CD4
þ CD25 þ cells in a secondary MLR Cells were activated in a primary MLR and then allodepleted by MACS, Ontak, the IT þ 6 mM NH 4 Cl, or by combined treatment with MACS followed by the IT þ NH 4 Cl. The cells were exposed to the IT or Ontak at the dose 10 À8 M for 24 h. The treated cells were washed twice by centrifugation in sterile PBS and cell viability was determined by Trypan blue staining. The treated cells were then re-stimulated in a secondary MLR for an additional 72 h by co-culturing them with irradiated PBMCs (25 Gy) from the same stimulator cells or from an unrelated third party donor. The responder cells were mixed with either the original stimulator cells or third party cells at a cell ratio of 2.5:1 and incubated in six-well flat bottom plates (Corning, NY, USA) at the concentration of 2.5 Â 10 6 responder cells per ml. The cells were then stained and analyzed by flow cytometry.
Selective depletion of CD8
þ CD25 þ cells activated in a primary MLR using the IT, Ontak or MACS The MLR was modified for the maximal activation of CD8 þ CD25 þ lymphocytes since, as compared to CD4 þ CD25 þ cells, these cells require prolonged stimulation. Six days were determined to be optimal for maximal activation of CD8 þ CD25 þ cells. PBMCs isolated from the blood of healthy donors were activated in a one-way MLR by co-culturing them with irradiated stimulator PBMCs À8 M IT þ 6 mM NH 4 Cl, or were left untreated. Cells treated with Ontak or the IT were then incubated again for another 24 h and then washed twice in PBS. Cells treated with MACS were depleted by the same method as previously described for CD4 þ CD25 þ T cells. To compare each method of depletion, the expression of CD25 on the activated and allodepleted cells was determined by flow cytometry immediately following treatment.
Reactivation of CD8
þ CD25 þ cells in a secondary MLR Following allodepletion, the remaining cells were reactivated in a secondary MLR with irradiated PBMCs from either the same donor or from a third party donor. Irradiated PBMCs were added twice at 72-h intervals. The responder and irradiated stimulator cells were mixed at a 3:1 ratio and diluted in complete medium such that the final concentration of the responder cells was 2 Â 10 6 /ml. After a 6-day incubation, the percentage of CD8 þ CD25 þ cells was determined by flow cytometric analysis.
Flow cytometric analysis
The expression of CD25 on the surface of cells was determined by three-color flow cytometry. Samples of 10 6 cells were transferred into 1.5 ml microcentrifuge tubes (USA Scientific, Ocala, FL, USA) and stained for 30 min in the dark with a mixture containing 3 ml each of three of the following MAbs: fluorescein isothiocyanate (FITC)-labeled anti-human CD3, phycoerythrin (PE)-labeled anti-human CD25, tricolor (TC)-labeled anti-human CD4 and allophycocyanin-(APC)-labeled anti-human CD8 (Caltag Laboratories, Burlingame, CA, USA). Three control tubes of 10 6 cells were each stained with a single MAb and one tube of unstained cells served as the negative control. Cells were washed twice in PBS, resuspended in 500 ml of PBS, and fixed with 1% paraformaldehyde (Sigma, St Louis, MO, USA). Cell suspensions were transferred into 5 ml flow cytometry tubes (Becton Dickinson, Franklin Lakes, NY, USA) and 50 000 events were subsequently analyzed on a FACscalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) using Paint-A-Gate software. Lymphocytes were gated from the whole-PBMC population using forward scatter (FSC) and side scatter (SSC), and the percentage of stained
cells was expressed as a proportion of the viable CD3
þ cell population. The cell viability after each treatment was determined by FACS following Annexin-V-propidium iodide double staining (BioSource International, Camarillo, CA, USA). Cells washed with PBS were resuspended at 2-3 Â 10 6 cells/ml in 
Results
The IT and MACS depleted PHA-activated CD4 þ CD25 þ cells more effectively than Ontak Each allodepletion method was first assessed using PHAactivated CD4 þ CD25 þ cells. Following each method of depletion, the cells were stained with MAbs and analyzed by flow cytometry for CD25 expression ( Figure 1A) . Data from three independent experiments are presented in the bar diagram in Figure 1B . Figure 2 . Dot plots obtained by FACS analysis of treated cells are presented in Figure 2A . As shown in Figure 2B, þ CD25 þ , respectively. As expected, the control anti-CD22 IT had no effect on CD4 þ CD25 þ cells. Our data demonstrate that the IT or MACS were equally effective in depleting alloreactive T cells whereas Ontak was ineffective.
CD4
þ CD25 þ cells allodepleted by the IT or by MACS retained their reactivity against third party cells We next re-stimulated cells allodepleted by Ontak, the IT þ NH 4 Cl, MACS, or by a combination of MACS and the IT in a secondary MLR with the same stimulator cells or with third party cells. Results from three independent experiments are presented in Figure 3 . Dot plots obtained by FACS analysis of reactivated cells are presented in Figure 3A . As shown in Figure 3B that Ontak was not effective in depleting alloreactive cells. In our control group, the difference between untreated MLR-activated cells re-stimulated after 72 h by the same donor cells vs by third party donor cells was also not significant (15.6272.9 vs 13.973.6%). Moreover, the viability of these cells was determined using Annexin-Vpropidium iodide double staining and FACS analysis. No significant differences were observed in viabilities of untreated cells, cells treated with the IT þ NH 4 Cl, Ontak, MACS or MACS followed by the IT (data not shown).
These results demonstrate that the cells allodepleted by the IT, MACS or both retained higher reactivity against third party cells while their reactivity against the same donor cells was significantly lower. There was no statistically significant difference among the three depletion methods of IT, MACS and MACS þ IT. In contrast, Ontak was ineffective.
The IT effectively depleted activated CD8 þ CD25
þ lymphocytes compared to Ontak or MACS To compare the effects of allodepleting CD8 þ CD25 þ cells by each agent, PBMCs were activated with irradiatedstimulator cells for 6 days in a primary MLR and then treated with the IT þ NH 4 Cl, Ontak or MACS. Following treatment, 1 Â 10 6 cells from each treatment group were stained and analyzed by flow cytometry. Cells were gated on the CD8 þ CD3 þ lymphocyte population and then analyzed for CD25 expression. Results from the primary MLR are presented in Figure 4 and are expressed as means7s.d. from four independent experiments. The percentage of CD8 þ T cells expressing CD25 following allodepletion with the IT was significantly lower than the percentage following treatment with Ontak or MACS (0.3170.12 vs 2.4270.25%; or 2.0470.45%, respectively). In addition, there was no significant difference in the percentage of CD8 þ CD25 þ cells depleted by the IT vs MACS þ the IT (0.3170.12 vs 0.03770.029%, respectively). Cell viability was observed to be low following MACS. Hence, the IT and the combination of MACS þ the IT were more effective than either Ontak or MACS in eliminating alloreactive CD8 þ CD25 þ T cells. Based on viability, the IT performed the best.
Treated cells from the primary MLR were re-cultured for 6 days in a secondary MLR either with irradiated PBMCs from the same unrelated donor or from a third party donor. Cells were then analyzed for expression of CD25. Results from the secondary MLRs are presented in Figure 4 .
When comparing activation by the same unrelated donor in primary vs secondary MLRs, there was no significant difference between cells depleted with the IT or MACS (0.3170.12 vs 1.170.60%, respectively, for the IT; and 2.070.45 vs 2.371.0%, respectively, for MACS). The same was true in comparing depletion in the primary vs the secondary MLR by MACS and the IT (0.0470.03 vs 0.3170.20%, respectively). However, the activation of the cells in the primary vs secondary MLRs was significantly different when cells were treated with Ontak (2.470.25 vs 6.372.2%, respectively). The untreated control cells reacted similarly in the primary vs secondary MLR (6.670.71 vs 9.472.1%, respectively). These data suggest that as compared to allodepletion with the IT or MACS, Ontak is not effective in eliminating alloreactive CD8 þ CD25 þ T cells. When comparing activation in secondary MLRs, there was a significant difference between IT-treated cells that were activated by the same donor vs cells activated by cells from a third party donor (1.170.6 vs 7.572.6%, respectively). The same was true in comparing MACS (2.371.0 No significant difference in depletion was observed using the IT vs MACS (P ¼ 0.14). The control anti-CD22 IT had no effect on CD4 The results of the secondary MLR show that allodepleted cells retained third party reactivity in secondary MLRs. In conclusion, the IT was most effective in allodepleting CD8
þ CD25 þ cells.
Discussion
Activated donor-derived T lymphocytes are the effector cells responsible for the development of acute GVHD in patients after HSCT. Both, CD4 þ and CD8 þ T cells play important roles not only in mediating GVHD but also in mediating GVL reactivity.
Several studies have reported the presence of different T cell clones that react against leukemic cells, nonleukemic host cells, or both. 24, 25 Therefore, it is critical to eliminate only the host-reactive donor T cells that cause GVHD, while preserving most of the cells that mediate GVL and antimicrobial immune responses. 1, 2, 4, 26, 27 Alloreactive T lymphocytes can be selectively depleted using an IT directed against CD25, a molecule that is upregulated following activation of the cells in an MLR. 7, 28 Allodepletion with this IT ex vivo has yielded encouraging results in several clinical trials. 9, 10, 12 However, since other methods for depleting CD25 þ cells might be equally effective or superior to the IT, and since two other agents are readily available, our study was designed to compare our IT to these agents. To this end, PBMCs activated in a one-way MLR were subjected to allodepletion by the anti-CD25 IT, anti-CD25 MACS, Ontak or IT plus MACS. The allodepleted CD4
þ CD25 þ and CD8 þ CD25 þ cells were analyzed by FACS for CD25 expression and then subjected to a secondary MLR to determine how successful allodepletion was and whether third party reactivity was preserved.
The major findings to emerge from these studies are as follows: (1) The IT, MACS, or the combination of MACS plus the IT effectively depleted alloreactive CD4 þ CD25 þ cells without decreasing third party reactivity in a secondary MLR. (2) The IT or the combination of MACS þ the IT were more effective in depleting alloreactive CD8 þ CD25 þ cells than Ontak or MACS alone. All remaining CD8
þ CD25 þ cells retained good reactivity against third party cells in a secondary MLR; except used the same IT to allodeplete T cells activated by recipient EBV-transformed lymphoblastoid cells in a preclinical study. Later this group 12 performed a clinical study comparing immune reconstitution after transplanting IT-allodepleted donor T cells in haploidentical patients. The incidence of acute GVHD (2/16), chronic GVHD (2/ 13) and mortality from infectious disease (1/16) was low. Patients receiving higher numbers of allodepleted cells showed accelerated T cell recovery. An effector memory phenotype on the majority of the T cells from these patients suggested that they were derived from infused donor cells. Nevertheless, allodepletion using this IT requires further optimization, comparison with other methods of allodepletion, and validation in larger patient groups.
Depletion of CD4 þ and CD8 þ cells from bone marrow grafts was an effective method in decreasing the incidence and severity of acute GVHD in high-risk patients. 14, 15 Other studies have demonstrated that alloreactive CD25 þ cells could be selectively depleted in vitro using anti-CD25 MACS, while preserving third party reactivity. 16, 17 However, results of clinical trials using anti-CD25 MACS have not yet been reported.
Although the IT, MACS or both significantly decreased the response of CD4 þ CD25 þ cells against the same stimulator cells, in accord with previous reports using this IT, 8, 24 we have confirmed that some alloreactive clones escaped treatment with these reagents. This could be due to the survival of some cells with low densities of CD25 or to the expansion of alloreactive clones presented at low frequencies. These remaining cells could account for residual low-grade GVHD in vivo. Whether large numbers of these cells transplanted into patients would mediate a GVL effect in the absence of high grade GVHD remains to be determined clinically.
Our second major finding shows that as compared to MACS and Ontak a single treatment with the IT is the most effective method for depleting alloreactive CD8 þ CD25 þ T cells. However, some alloreactive CD8 þ CD25 þ cells still remained after this treatment. The slow expansion of low frequency CD8 þ alloreactive clones over 12 days in culture may also explain this observation.
Since immunodepletion is based on CD25 expression, the density of this antigen on cells may contribute to the differences observed in allodepleting CD4 party cells. However, these results contradict the results from clinical studies that have been conducted to examine the ability of Ontak to treat steroid-refractory GVHD in vivo. 29, 30 Ho et al. 29 conducted a phase 1 study in patients with steroid refractory acute GVHD and 71% patients responded with complete (12 of 24) or partial resolution (5 of 24) of GVHD following intravenous treatment with Ontak. It is possible that the in vivo behavior of Ontak is different and that the drug targets additional cell types and/ or that the depletion of cells in the matched transplant setting yields clinically useful results.
Recently, it has been reported that CD4 þ CD25 þ regulatory (Treg) T cells can mediate transplant tolerance. 31 But only 1-3% of CD4 þ CD25 þ cells that have high expression levels of CD25 were confirmed to have suppressive capacity. 32 CD25 is not an ideal marker to designate Treg cell function since it is also upregulated on T cells following activation. Currently, the forkhead transcription factor, Foxp3, 33 and CD27 34 appear to distinguish Treg cells from activated T cells. Based on preliminary studies, the IT appears to reduce the number of Treg cells. 34 To what extent this has resulted in low-grade GVHD in published studies 34, 35 is unclear and remains to be studied. In conclusion, our study has determined that our anti-CD25 IT and anti-CD25 MACS are equally effective in depleting alloreactive CD4 þ CD25 þ cells and that the IT was superior to MACS in depleting alloreactive CD8 þ CD25 þ cells. Ontak was not effective in depleting either CD4 þ CD25 þ or CD8 þ CD25 þ cells. This study, along with the previous reports, indicates that the IT is the treatment of choice for allodepletion prior to BMT, but that anti-CD25 MACS are highly effective as well. However, further studies are needed to optimize the treatment regimen to deplete all alloreactive clones that may expand over time and have the potential to mediate GVHD. It will also be important to determine whether depletion of Treg cells plays a role in mediating low grade or chronic GVHD.
